New Delhi: Serum Institute of India (SII) is expected to begin clinical trials of Novavax’s COVID-19 vaccine ‘Covovax’ for children this July, according to media reports. SII is also planning ...
Novavax’s COVID-19 vaccine Covovax, to be also made in this country by Serum Institute of India (SII), has been found to be more than 90 per cent effective against coronavirus, ...
New Delhi: Serum Institute of India (SII) got the approval to conduct Phase 2 and 3 clinical trials for Novavax’s COVID-19 vaccine candidate in the country. The green signal came ...
Pune: India's premier vaccine manufacturer, Serum Institute of India (SII), has sought permission from Drugs Controller General of India (DCGI) to conduct a study trial using US-based Novavax's COVID-19 vaccine. ...
Even if a coronavirus vaccine is developed successfully by early next year, there won’t be enough to administer all global citizens till the end of 2024, Serum Institute of India’s ...
India’s Serum Institute and Novavax Inc whose COVID-19 vaccine candidate showed promising results in the initial clinical trials have signed an exclusive supply and license agreement for the production of ...
Copyright © 2025 Frontier Media
